戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  been made in our understanding of pediatric metabolic bone disease.
2 investigating the treatment of patients with metabolic bone disease.
3 om additional surveillance and management of metabolic bone disease.
4 eta 2, may contribute to the pathogenesis of metabolic bone disease.
5     Diabetes osteoporosis (DOP) is a chronic metabolic bone disease.
6 e a target for controlling mineralization in metabolic bone disease.
7 otential targets for the clinical therapy of metabolic bone diseases.
8 enues for enhancing bone repair and treating metabolic bone diseases.
9 nimal models with which to gain insight into metabolic bone diseases.
10                 It is the second most common metabolic bone disease after osteoporosis, affecting 3%-
11 me a useful tool for assessing patients with metabolic bone disease and evaluating novel drugs being
12 , potentially making it possible to diagnose metabolic bone disease and track the impact of treatment
13 ased on knowledge gained in the treatment of metabolic bone diseases and in periodontal clinical tria
14 rveillance for inflammatory bowel disorders, metabolic bone disease, and malignancy is paramount when
15 y dialysis, improved nutrition, treatment of metabolic bone disease, and the use of recombinant human
16 on, and severe disease with renal stones and metabolic bone disease arises less frequently now than i
17                       Wwox(-/-) mice develop metabolic bone disease, as a consequence of reduced seru
18 identified and comprehensively evaluated for metabolic bone disease at a median of 16 days (range 9-3
19 ldren with perpetrator-admitted child abuse, metabolic bone disease, birth trauma, or injury caused b
20 treatment of Paget disease of bone and other metabolic bone diseases but, to our knowledge, it has no
21 ic fibrosis-related diabetes, renal disease, metabolic bone disease, cancers, drug allergies and toxi
22                            Osteoporosis is a metabolic bone disease characterized by low bone mass an
23                       Osteoporosis (OP) is a metabolic bone disease characterized by reduced bone den
24 ly by multidisciplinary teams organized by a metabolic bone disease expert.
25 imal models that impact our understanding of metabolic bone disease have evolved dramatically.
26 e evaluation of the prevalence and extent of metabolic bone disease in RTS.
27             Deregulation of Cbfa1 results in metabolic bone diseases including osteoporosis and osteo
28 ytokines play a key role in various forms of metabolic bone diseases, including osteopenia and osteop
29                                              Metabolic bone disease is a common complication of chron
30               Preterm infants are at risk of metabolic bone disease (MBD) because of an inadequate mi
31 -related complications-including fatigue and metabolic bone disease-remain unavailable.
32 iphosphonate ((99m)Tc-MDP) in metastatic and metabolic bone disease require the measurement of free t
33           The model is also able to simulate metabolic bone diseases such as estrogen deficiency, vit
34 ly diagnosis and evaluation of therapies for metabolic bone diseases such as osteoporosis and some ca
35 entiation, and possibly for the treatment of metabolic bone diseases such as osteoporosis.
36  retarding the development or progression of metabolic bone disease; there is minimal risk, providing
37 thologic cascade leading to hyperthyroidism, metabolic bone disease, vascular calcification, and card